[1]刘 静,史艳平,赵珍珍,等.清肺疏络饮对肺炎支原体肺炎小鼠治疗机制研究[J].陕西中医,2023,(3):290-293.[doi:DOI:10.3969/j.issn.1000-7369.2023.03.004]
　LIU Jing,SHI Yanping,ZHAO Zhenzhen,et al.Therapeutic mechanism study on Qingfei Shuluoyin on mycoplasma pneumoniae pneumonia in mice[J].,2023,(3):290-293.[doi:DOI:10.3969/j.issn.1000-7369.2023.03.004]
点击复制

清肺疏络饮对肺炎支原体肺炎小鼠治疗机制研究
分享到：

《陕西中医》[ISSN:1000-7369/CN:61-1281/TN]

卷:
期数:
2023年3期
页码:
290-293
栏目:
基础研究
出版日期:
2023-03-05

文章信息/Info

Title:
Therapeutic mechanism study on Qingfei Shuluoyin on mycoplasma pneumoniae pneumonia in mice
作者:
刘 静1; 史艳平1; 2; 赵珍珍2; 田纪凤2; 吉 慧2; 李 霞2; 邱 锐1
(1.陕西中医药大学,陕西 咸阳 712046; 2.西安市儿童医院,陕西 西安710003)
Author(s):
LIU Jing; SHI Yanping; ZHAO Zhenzhen; TIAN Jifeng; JI Hui; LI Xia; QIU Rui
(Shaanxi University of Chinese Medicine,Xianyang 712046,China)
关键词:
肺炎支原体肺炎;  清肺疏络饮;  阿奇霉素;  细胞黏附;  E-cd蛋白
Keywords:
Mycoplasma pneumoniae pneumonia;  Qingfei Shuluoyin;  Azithromycin;  Cell adhesion;  E-cd protein
分类号:
R 375
DOI:
DOI:10.3969/j.issn.1000-7369.2023.03.004
文献标志码:
A
摘要:
目的:观察清肺疏络饮对肺炎支原体肺炎小鼠的疗效及其作用机制。方法:选用50只SPF级BALB/c小鼠,按随机数字表法分为正常组、模型组、阿奇霉素组、清肺疏络饮组、联合组,各10只。除正常组外,其余各组小鼠均采用滴鼻接种肺炎支原体菌株造模。造模成功后,阿奇霉素组给予阿奇霉素0.18 ml/20g灌胃,清肺疏络饮组给予清肺疏络饮0.15 ml/20g灌胃,联合组按照上述剂量联合用药,正常组及模型组给予0.9%氯化钠注射液0.20 ml/20 g灌胃,各组小鼠均灌胃7 d。观察肺组织病理变化,检测肺组织内肺炎支原体(MP)水平、P1和E-cd蛋白表达水平。结果:造模后小鼠肺组织镜检符合肺炎改变。灌胃治疗后,阿奇霉素组、清肺疏络饮组小鼠的肺炎改善显著,联合组效果最佳。模型组肺组织P1和E-cd蛋白表达水平较正常组升高,差异有统计学意义(均P<0.05)。治疗后联合组P1和E-cd蛋白表达水平均低于模型组,差异有统计学意义(均P<0.05)。治疗后,清肺疏络饮组、阿奇霉素组小鼠MP均低于模型组,且联合组MP水平最低。结论:清肺疏络饮可以减轻肺炎支原体肺炎小鼠肺部炎症,其作用机制可能与抑制肺组织P1和E-cd蛋白表达,降低MP水平有关。
Abstract:
Objective:To observe the efficacy and mechanism of Qingfei Shuluoyin on mice with mycoplasma pneumoniae pneumonia.Methods:50 BALB/c mice with SPF grade were assigned via the random number table method to the normal group,model group,azithromycin group,Qingfei Shuluoyin group and combinatorial group,each group of 10 mice.Except for the normal group,the other groups were inoculated with mycoplasma pneumoniae strains intranasally to mold.After the success of the model,the azithromycin group were treated with 0.18 ml/20g of azithromycin by intragastric administration,and the dose of Qingfei Shuluoyin reached to 0.15 ml/20g for intragastric administration of the Qingfei Shuluoyin group.The Combinatorial group were simultaneously treated with co-medication of azithromycin and Qingfei Shuluoyin according to their doses mentioned above.Meanwhile,the normal group and the model group were treated with 0.20 ml/20g of 0.9% sodium chloride injection for a total of 7 days.After that,the lung tissue was obtained to observe its pathological changes,and the levels of mycoplasma pneumoniae(MP)and the expression levels of P1 and E-cd proteins in the lung tissue were also measured.Results:The results of microscopic examination in the lung tissue of model mice exhibited the consistency with the changes of pneumonia.After treatment,the pneumonia significantly improved significantly in the azithromycin group and the Qingfei Shuluoyin group,and it possessed the best therapeutic effect in the combinatorial group.The expression levels of P1 and E-cd protein in the lung tissue of the model group were higher than those in the normal group,difference statistically significant(all P<0.05).After treatment,the expression levels of P1 and E-cd protein in the combinatorial group were lower than those in the model group,difference statistically significant(all P<0.05).After treatment,the expression levels of MP in the Qingfei Shuluoyin group and the azithromycin group were lower than those in the model group,and MP in the combinatorial group was the lowest.Conclusion:Qingfei Shuluoyin can reduce lung inflammation in mice with mycoplasma pneumoniae pneumonia,and its mechanism may be related to the inhibition of Qingfei Shuluoyin to P1 and E-cd protein expressions and MP levels in lung tissue.

参考文献/References:

[1] 辜德明,周家仍,罗 旋,等.细胞因子IL-6、TNF-α评估小儿支原体肺炎病情进展和预后[J].中华肺部疾病杂志:电子版,2021,14(4):505-507.
[2] 叶 菁.血清肝细胞生长因子在肺炎支原体肺炎儿童中检测意义的探讨[D].天津:天津医科大学,2020.
[3] 徐怀彦,尚莉丽.小儿支原体肺炎诊疗研究进展[J].中医临床研究,2021,13(29):146-148.
[4] 房亚菲,刘丽娟,霍 晨.儿童社区获得性肺炎的流行特征和临床表现及病原菌调查[J].中华医院感染学杂志,2020,30(5):752-756.
[5] 赵珍珍,史艳平,邱 锐,等.清热活血方联合阿奇霉素治疗儿童肺炎支原体肺炎临床研究[J].陕西中医,2021,42(5):616-619.
[6] 包 瑛,雷春莲.肺炎支原体肺炎的研究进展[J].陕西医学杂志,2002,31(10):898-901.
[7] 栾晓东,盖延红,曲延刚.E-CD与胃癌临床病理特征的关系探讨[J].陕西医学杂志,2002,31(5):409-411.
[8] 彭凯岚,曾焱华.肺炎支原体P1蛋白的研究进展[J].中国人兽共患病学报,2021,37(4):362-367.
[9] 王守满,汤恢焕.胆囊癌组织中CD44V6和E-CD的表达及意义[J].中国医师杂志,2004,6(7):909-910.
[10] 韩晓莉.沙参麦冬汤加减治疗小儿支原体肺炎的临床疗效观察[J].黑龙江中医药,2020,49(2):25-26.
[11] 邹武军,郭焕利,李晓丽,等.麻甘颗粒联合阿奇霉素治疗小儿支原体肺炎疗效研究[J].陕西中医,2019,40(11):1582-1585,1589.
[12] 褚明慧.连花清瘟颗粒与阿奇霉素共同治疗小儿肺炎支原体肺炎的效果分析[J].当代医学,2021,27(1):88-91.
[13] 秦一冰,曲妮妮,郑 忻,等.基于网络药理学探讨柴胡-黄芩治疗新型冠状病毒肺炎的作用机制[J].中华中医药学刊,2020,38(6):259-260.
[14] 蒙艳丽,徐佳莹,王晓溪,等.黄芩苷抗肺炎支原体研究[J].中华中医药学刊,2020,38(2):158-161,279.
[15] 王 颖,李建来,刘俊俊.贝母瓜蒌合剂治疗儿童肺炎支原体肺炎临床研究[J].河南中医,2019,39(12):1858-1861.
[16] 栾智华,任晋宏,薛慧清,等.黄芪糖蛋白对肺纤维化小鼠肺组织中α-SMA表达的影响[J].中华中医药学刊,2020,38(6):197-200,274-276.
[17] 景永帅,马云凤,王非凡,等.丹参多糖的含量测定、结构表征及药理活性研究进展[J].中国药房,2020,31(16):2037-2042.
[18] 邹菊英,陈胜璜,雷 昌,等.半夏炮制前后HPLC图谱的比较[J].湖南中医药大学学报,2010,30(9):127-129.
[19] 闫 峰,王效民.MAPK信号转导通路与肝癌细胞多药耐药[J].陕西医学杂志,2007,36(10):1400-1402.
[20] 华 刚,管爱芬,孟 静.地龙散加减治疗坐骨神经痛86例[J].陕西中医,2006,27(5):524-525.

相似文献/References:

[1]贺 辉,刘正艳,梁丽娜,等.宣肺清毒汤治疗小儿支原体肺炎疗效及对患者血清炎性因子表达水平的研究[J].陕西中医,2019,(5):627.
　HE Hui,LIU Zhengyan,LIANG Lina,et al.Effect of Xuanfei Qingdu decoction on children of mycoplasma pneumonia and its influence on expression level of serum inflammatory factors[J].,2019,(3):627.
[2]赵珍珍,史艳平,邱 锐,等.清热活血方联合阿奇霉素治疗儿童肺炎支原体肺炎临床研究[J].陕西中医,2021,(5):616.[doi:DOI:10.3969/j.issn.1000-7369.2020.05.018]
　ZHAO Zhenzhen,SHI Yanping,QIU Rui,et al.Effect of Qingre Huoxue decoction with Azithromycin on mycoplasma pneumoniae pneumonia in children[J].,2021,(3):616.[doi:DOI:10.3969/j.issn.1000-7369.2020.05.018]

备注/Memo

备注/Memo:
基金项目:陕西省自然科学基础研究计划项目(2022JM-534); 西安市科技计划项目[2019114613YX001SF034(8)]
更新日期/Last Update: 2023-03-13